	Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION		ATTORNEY DOCKET NO. 0975.1005-036		APPLICATION NO. 10/665,971	
DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Junming Le		FILING DATE September 19, 2003		
MON 0 5 500 ET	TING OF REFERENCES	EXAMINER	1 -	RMATION NO.	GROUP	
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	October 30, 2007  Use several sheets if necessary)	Phillip Gambel	5342		1644	

		U.S.	PATENT DOCUMENTS	S
EXAM -INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
NS.	AA7	5,506,265	4/9/1996	Blitstein-Willinger

EXAMINER PHULP GAMPA 2/14/08

746324\_

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION	ATTORNEY DOCKET NO. 0975.1005-036  FIRST NAMED INVENTOR Junming Le		APPLICATION NO. 10/665,971  FILING DATE September 19, 2003	
DISCLOSURE STATEMENT IN AN APPLICATION				
LISTING OF REFERENCES	EXAMINER	CONFI	RMATION NO.	GROUP
October 30, 2007	Phillip Gambel	5342	5342	
(Use several sheets if necessary)				

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
R	AF	R12	Bard, F. et al., "Peripherally Administered Antibodies Against Amyloid β-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease," Nat. Medicine, 6(8): 916-919 (2000).	
	AS	512	Borrebaeck, C.A.K. (ed.), Antibody Engineering, 2nd Edition, Pub. Oxford University Press, p. 291 (1995).	
	ΑΊ	Γ12	Brok, H.P.M. et al., "Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using an Anti-IL-12p40 Monoclonal Antibody," J. Immunol., 6554-6563 (2002).	
	Al		Cornillie, F. et al., "Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease," Aliment. Pharmacol. Ther., 15: 463-473.	
	A۱		Fong, Y. et al., "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1ß and Interleukin 6 Appearance During Lethal Bacteremia," J. Exp. Med., 170:1627-1633 (1989).	
	. A\		Geysen, H.M. et al., "A Synthetic Strategy for Epitope Mapping," In Proc. Tenth Amer. Peptide Symposium, pp. 519-523 (Garland R. Marshall, ed. 1987).	
Π	A	X12	Goh, C., "Tumor Necrosis Factors in Clinical Practice," Ann. Acad. Med. Singapore, 19(2): 235-239 (1990).	
	AY	Y12	Herve, P. et al., "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," Lymphoma Res. 9:591 (1990). (Abstract No. 3.25).	
	AZ	ĺ	Kawasaki, H. et al., "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," Infect. Immun., 57(10):3131-3135 (1989).	
	AF		Socher, S. et al., "Antibodies against amino acides 1-15 of tumor necrosis factor block its binding to cell surface receptor," Proc. Natl. Acad. Sci., USA, 84: 8829-8833 (1987).	
		\$13	Von Asmuth, E.J.U. et al., "Tumour Necrosis Factor Alpha (TNF-α) and Interleukin 6 in a Zymosan-Induced Shock Model," Scand. J. Immunol., 32:313-319 (1990).	
A	ΑΊ	[13	Yan, L. et al., "Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor Alpha," Chinese J. Biotech., 7(2): 121-126 (1991).	

DATE CONSIDERED PHUP CEANNER EXAMINER